Clinical Trial Update: Intuniv vs Placebo in the Treatment of Childhood Intermittent Explosive Disorder [Phase 4]

View source ↗

Summary

A Phase 4 trial comparing Intuniv to placebo in children with Intermittent Explosive Disorder has completed. Results were posted in November 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder
• Intermittent Explosive Disorder
• Oppositional Defiant Disorder

Drugs mentioned

• Intuniv (guanfacine hydrochloride)

Snippet

Sponsor: New York State Psychiatric Institute | Conditions: Intermittent Explosive Disorder, Childhood Aggression | Phase 4 | Status: COMPLETED | Results posted: 2017-11-06